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Abstract
The adaptor protein NHERF1/EBP50 (Na/H exchanger regulatory
factor 1/ezrin-radixin-moesin-binding phosphoprotein 50) emerged
recently as an important player in breast cancer progression.
Consisting of two tandem PDZ domains linked to a carboxyl-terminal
ezrin-binding region, NHERF1 assembles macromolecular complexes
at the apical membrane of epithelial cells in many epithelial tissues,
including the mammary gland. Involved initially in trafficking and
regulation of transmembrane ion transporters and G protein-coupled
receptors, NHERF1 also couples molecules involved in cell growth,
such as the platelet-derived growth factor receptor (PDGFR) and
PTEN (phosphatase and tensin homolog deleted on chromosome
10). In the previous issue of Breast Cancer Research, Pan and
colleagues show an inhibitory action of NHERF1 on the
phosphoinositide-3 kinase (PI3K)/Akt pathway in breast cancer cells
via interaction of NHERF1 with PTEN, the physiological antagonist of
the PI3K. Additionally, they show that NHERF1 expression confers
susceptibility to PDGFR pharmacological inhibition depending on
the presence of PTEN tumor suppressor.
Breast cancer is a complex disease comprising multiple
pathological types and molecular profiles that determine
various clinical outcomes and responses to therapy.
Molecular cancer treatments recently came into focus, and
targeted molecular therapies, such as trastuzumab, have
already provided effective new drugs against breast cancer.
New oncogenic pathways are studied for their potential to
become therapeutic molecular targets, one such pathway
being the phosphoinositide-3 kinase (PI3K)/Akt pathway that
is physiologically repressed by the PTEN (phosphatase and
tensin homolog deleted on chromosome 10) tumor
suppressor in normal tissues and cells. In the previous issue
of Breast Cancer Research, Pan and colleagues [1] show
that Na/H exchanger regulatory factor 1 (NHERF1), an
adaptor protein recently shown to be involved in the
progression of breast cancer, acts as a brake on the PI3K
signaling downstream of the platelet-derived growth factor
receptor (PDGFR) in the mammary gland. These findings
extend and confirm previous studies in mouse embryonic
fibroblasts that have exemplified a ternary complex bridged by
NHERF1 between PDGFR and PTEN tumor suppressor
exerting an inhibitory action on the PI3K signaling [2]. Pan
and colleagues further substantiate the negative role of
NHERF1 on the PI3K pathway by showing significant
activation of Akt in the mammary gland of NHERF1-deficient
mice. The group then explores the role of this inhibitory loop
in the sensitivity of breast cells to the PDGFR (and Bcr-Abl)
inhibitor STI-571, a drug that is in clinical trial for the
treatment of metastatic breast cancer [3], among other types
of cancer. They find that NHERF1 expression confers
sensitivity to STI-571 treatment in PTEN-positive breast
cancer cells but does not affect the response to the drug in
PTEN-negative breast cancer cells. Alternatively, expression
of NHERF1 in a normal breast cancer cell line (MCF10A)
renders cells sensitive to STI-571 only in the presence of
wild-type endogenous PTEN. Thus, it is tempting to correlate
the sensitivity of breast cancer cells to STI-571 with the
presence of these two biomarkers, NHERF1 and PTEN, and
the study by Pan and colleagues clearly suggests this
connection.
Dai and colleagues previously have reported an increased
deletion rate (58%) of one NHERF1 allele and also mutation
with loss of heterozygosity in 3% of breast cancer cell lines
and primary tumors [4]. Similarly to the observation that
mutations in the PI3K catalytic subunit (PIK3CA) are mutually
exclusive with PTEN mutations in breast cancer [5], Pan and
colleagues observe an inverse correlation between the
deletion of NHERF1 allele and mutations of either PTEN or
PIK3CA genes in breast cancer cell lines [1]. These data
bring genetic evidence for NHERF1 integration in the PI3K
pathway and point to a tumor-suppressor role of NHERF1 in
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breast cancer. Further functional validation of the anti-
proliferative role of NHERF1 in breast cancer cells has been
provided by NHERF1 silencing experiments [6].
Interestingly, recent reports described an overexpression of
NHERF1 in breast cancer as compared with normal
mammary tissue [7,8]. The human NHERF1 gene promoter
contains estrogen receptor (ER) response elements [9], and
the increased NHERF1 expression has been detected in
more than 90% of ER-positive tumors [7,8,10]. Conversely,
NHERF1 is completely absent in approximately two thirds of
the more aggressive ER-negative breast tumors [8,10], again
suggesting a tumor-suppressor role for NHERF1. The
apparently opposing situations may be reconciled by the
notion that NHERF1 is an adaptor protein that assembles
signaling proteins in complexes, and its loss or its
overexpression equally disrupt these complexes, the former
by lack of scaffolding and the latter by titrating down other
components of the complex. The latter appears to be even
more conspicuous if the overexpression of the adaptor protein
occurs in a cell compartment different from its normal intra-
cellular distribution. Indeed, all of the reports showing
NHERF1 overexpression in breast tumors point to an
accumulation of NHERF1 in the cytoplasm as opposed to the
physiological membrane localization of the molecule in normal
breast tissue [7,8,10]. The possibility that delocalized
NHERF1 may scaffold complexes in the cytoplasm, thus
sequestering signaling molecules away from the plasma
membrane, deserves future consideration. On the other hand,
in vivo data from NHERF1-deficient animals have clearly
shown that the lack of NHERF1 from the membrane
destabilizes both membrane-associated and transmembrane
proteins [11,12]. It is very likely that in the ER-positive breast
tumors displaying NHERF1 overexpression, a combination of
cytoplasmic overexpression and delocalization from the
plasma membrane contributes to the reported enhanced
invasiveness of these tumors [7,8]. In this respect, the matter
regarding the mechanism of NHERF1 recruitment to the
plasma membrane is open. Many membrane-targeting
mechanisms have been proposed, including phosphorylation
of the first PDZ domain [13], direct binding to lipids via the
tandem PDZ domains [14], or recruitment by the cortical
ezrin [15], and the predominance or contribution of these
mechanisms for NHERF1 membrane localization in mammary
cells awaits further study.
In view of the preliminary pharmacological studies presented
by Pan and colleagues in this issue, the presence of subsets
of breast tumors that present distinct expression patterns of
NHERF1 raises a number of questions about the possibility of
using NHERF1 as a biomarker. Are these tumor subsets
reacting differently to PDGFR inhibitors, and is this reactivity
correlated with PTEN or PDGFR expression levels? Are other
PI3K/Akt pathway-targeted therapies effective on the cells
that have upregulated PI3K activity due to loss of NHERF1?
Could the NHERF1-deficient mice be used as a model,
perhaps in combination with other genetic alterations
occurring in human breast cancer, to test the efficacy of new
therapies? It becomes increasingly apparent that the under-
standing of the tumor-suppressive functions of NHERF1 and
of the mechanism pertaining to its subcellular localization will
provide the necessary foundation for designing personalized
effective breast cancer therapeutic solutions.
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